Inozyme Pharma Inc. (INZY)
NASDAQ: INZY
· Real-Time Price · USD
4.00
0.00 (0.00%)
At close: Jun 30, 2025, 3:59 PM
Inozyme Pharma Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | n/a | n/a | n/a | n/a | n/a | n/a | 333K | 331K | 324K | n/a | 299K | 285K | 281K | 281K | 167K | 167K | 158K |
Gross Profit | n/a | n/a | n/a | n/a | n/a | n/a | -333K | -331K | -324K | n/a | -299K | -285K | -281K | -281K | -167K | -167K | -158K |
Operating Income | -27.69M | -27.17M | -24.85M | -27.66M | -24.34M | -22.81M | -18.07M | -16.39M | -18.37M | -19.53M | -16.91M | -15.39M | -16.84M | -18.76M | -14.26M | -12.65M | -10.97M |
Interest Income | 1.12M | 1.48M | 1.78M | 2.03M | 2.37M | 4.58M | 1.42M | 1.61M | 1.33M | 815K | 737K | 321K | 60K | 43K | 47K | 58K | 63K |
Pretax Income | -28.04M | -27.07M | -24.57M | -27.03M | -23.35M | -21.54M | -16.64M | -15.58M | -17.4M | -18.54M | -16.37M | -15.26M | -16.88M | -18.75M | -14.28M | -12.54M | -11.05M |
Net Income | -28.04M | -27.07M | -24.57M | -27.03M | -23.35M | -21.54M | -16.64M | -15.58M | -16.23M | -18.54M | -15.83M | -14.94M | -16.93M | -18.75M | -14.28M | -12.54M | -11.05M |
Selling & General & Admin | 5.41M | 4.7M | 4.96M | 5.91M | 5.23M | 4.83M | 4.73M | 4.73M | 6.51M | 5.7M | 4.72M | 5.38M | 5.03M | 5.21M | 4.92M | 4.43M | 4.37M |
Research & Development | 20.38M | 22.47M | 19.89M | 21.76M | 19.11M | 17.98M | 13.34M | 11.67M | 11.86M | 13.84M | 12.19M | 10.01M | 11.81M | 13.55M | 9.35M | 8.22M | 6.6M |
Other Expenses | 1.9M | n/a | n/a | n/a | n/a | n/a | 20K | -28K | -34K | n/a | -197K | -191K | -105K | -40K | -65K | 57K | -141K |
Operating Expenses | 27.69M | 27.17M | 24.85M | 27.66M | 24.34M | 22.81M | 18.07M | 16.39M | 18.37M | 19.53M | 16.91M | 15.39M | 16.84M | 18.76M | 14.26M | 12.65M | 10.97M |
Interest Expense | 1.41M | 1.42M | 1.42M | 1.4M | 1.32M | 3.33M | n/a | 771K | 328K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 27.69M | 27.17M | 24.85M | 27.66M | 24.34M | 22.81M | 18.07M | 16.39M | 18.37M | 19.53M | 16.91M | 15.39M | 16.84M | 18.76M | 14.26M | 12.65M | 10.97M |
Income Tax Expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -1.17M | n/a | -540K | -321K | 45K | -3K | -47K | -58K | -63K |
Shares Outstanding (Basic) | 64.28M | 62.81M | 63.28M | 61.94M | 61.77M | 61.77M | 56.76M | 44.86M | 43.72M | 40.71M | 43.66M | 39.7M | 23.69M | 23.64M | 23.64M | 23.49M | 23.43M |
Shares Outstanding (Diluted) | 64.28M | 62.81M | 63.28M | 61.94M | 61.77M | 61.77M | 56.76M | 44.86M | 43.72M | 40.71M | 43.66M | 39.7M | 23.69M | 23.64M | 23.64M | 23.49M | 23.43M |
EPS (Basic) | -0.44 | -0.43 | -0.39 | -0.44 | -0.38 | -0.35 | -0.29 | -0.35 | -0.37 | -0.46 | -0.36 | -0.38 | -0.71 | -0.79 | -0.6 | -0.53 | -0.47 |
EPS (Diluted) | -0.44 | -0.43 | -0.39 | -0.44 | -0.38 | -0.35 | -0.29 | -0.35 | -0.37 | -0.46 | -0.36 | -0.38 | -0.71 | -0.79 | -0.6 | -0.53 | -0.47 |
EBITDA | -26.46M | -25.48M | -22.96M | -25.45M | -21.84M | -17.91M | -16.3M | -15.25M | -16.76M | -19.34M | -16.72M | -15.21M | -16.66M | -18.57M | -14.1M | -12.49M | -10.81M |
EBIT | -26.63M | -25.65M | -23.15M | -25.64M | -22.02M | -18.21M | -16.64M | -15.58M | -17.08M | -19.53M | -16.91M | -15.39M | -16.84M | -18.76M | -14.26M | -12.65M | -10.97M |
Depreciation & Amortization | 176K | 177K | 195K | 188K | 182K | 306K | 333K | 331K | 324K | 198K | 299K | 285K | 281K | 281K | 167K | 167K | 158K |